Johnson & Johnson partners with Sail Biomedicines on in vivo CAR-T programs, takes option to buy Sail for $2.58 billion
PUBT · 2d ago
Share
Listen to the news
- Johnson & Johnson entered a strategic collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases.
- Upfront consideration totals USD 785 million, including a USD 465 million equity investment; milestone payments of USD 140 million are tied to development progress.
- The deal grants an exclusive option to acquire Sail for USD 2.58 billion, positioning the program as a potential immune-reset approach in autoimmune disease.
- If the option is exercised, the company expects adjusted operational EPS dilution of about USD 0.18 in 2026, rising to about USD 1.28 in 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending